Connect with us

Menopause

“There is a huge need for both support and education about women’s health”

By Afua Basoah, Head of Health Strategy for RAPP UK

Published

on

For generations, women have lived with health and care systems that are mostly designed by men, for men.

Despite representing 51 per cent of the population, women are still significantly underrepresented in clinical trials and research. This has meant that not enough is known about conditions that only affect women, or about how conditions that affect both men and women impact women in different ways.

This gender gap contributes to worse health outcomes for women, with much less known about female health conditions than those that also or only affect men.  In the UK, women have a longer life expectancy than men, with life expectancy at birth being 83.1 for women and 79.4 years for men in 2017 to 2019. However, women in the UK spend a greater proportion of their lives in ill health and disability.

In summer 2021, the UK government opened a consultation process to inform the development of a national Women’s Health Strategy. The ambition is to build a health system that better understands and is, therefore, responsive to the realities and needs of women throughout their lives.

There is a huge need for both support and education about all aspects of women’s health. Personalised, accessible and delivered in a way that evolves as their lives change.  As women’s healthcare becomes an increasing priority, the femtech industry is rising to meet the challenge. The industry has already demonstrated impressive early wins and with appropriate access to funding, greater disruption could be ahead.

Afua Basoah, Head of Health Strategy for RAPP UK

In 2019, the femtech industry generated $820.6m in global revenue and received $592m in venture capital investment. Femtech pioneers, many of whom are female-founded, have benefited from cultural shifts, sparked by events such as the #MeToo movement, a growing interest in diversity and inclusion and pandemic-related digital acceleration.

While the US accounts for the lion’s share of femtech startups, the UK comes second in a market predicted to be worth in excess of $75.1B (£60.7B) by 2025.   The industry represents a broad range of companies that are focused on developing technology aimed at improving women’s health and wellbeing that tend to fall into four categories: healthcare and diagnostics, reproductive health, pregnancy and family care and general health and wellness.

Of these, reproductive health, pregnancy and family care currently dominate the market and according to a recent McKinsey report “there are still significant white spaces” for growth.

The disruption in this space is driven by the need to create inclusive, individualised experiences that meet the unique identities, values and personal needs of women. The one size fits all approach has been sized out.

“The ability to understand the whole woman – her genetics, aspirations, experiences as well as unmet her health needs, provides an opportunity to holistically signpost the right solutions that takes her on a journey that touches every aspect of her well-being”.

Here, Idia Elsmore Dodsworth, co-founder of the AI-based reproductive health monitoring app, Tinto, has highlighted the fact that there is a real shift towards ‘well-care’ versus ‘sick-care’ in the femtech space.

Embedding AI into their own product has helped ensure granularity of data inputs that allows for “super-tailored” content that empower users to manage their health as seamlessly and effortlessly as with other aspects of their lives, and on their terms.

Below are a selection of femtech organisations to keep an eye on:

Tinto

Founders: Dr Hannah Allen and Idia Elsmore Dodsworth

Year founded: 2019

Total funding: Undisclosed seed funding

As a provider of AI-based software solutions for reproductive health monitoring, the mission of the Tinto app is to nurture women through modern motherhood, enabling mothers to understand the full picture of their wellbeing, and to build a network through meaningful connection and proactive, personalised guidance.

The company offers a mobile app that allows users to communicate with health and wellbeing providers. It provides a curated online community where members can access information and advice from like-minded women going through similar challenges.  It also provides online articles regarding baby health, women’s health and topics beyond motherhood.

Elvie

Founder: Tania Boler

Year founded: 2013

Total funding: £116m

Elvie is a London-headquartered firm that manufacturers technology hardware for women. The first product by the company was the Elvie Trainer, an app-connected Kegal trainer. Followed by the Elvie Pump a quiet, wireless electric pump.

Last September it closed £70m in its Series C funding round to continue diversifying its product range.

Vira Health

Founders: Andrea Berchowitz and Dr Rebecca Love

Year founded: 2020

Total funding: £11.2m

London-based Vira Health focuses on women’s healthcare and improving the gathering and use of female data in healthcare.

Its first product is a menopause subscription app called Stella which guides women through menopause with tailored treatments based on the users’ symptoms.

Last month Vira Health raised £9m in a funding round to add new features to its menopause app, including telehealth and prescriptions.

Clementine

Founder: Kim Palmer

Year founded: 2017

Total funding: £1m

Clementine is a mental health app for women that uses hypnotherapy to lower stress levels and build confidence. In the subscription-based app there are sleep sessions, confidence courses, anti-anxiety courses and mantras.

The app was created after founder Kim Palmer suffered with panic attacks during pregnancy. Earlier in the year, Clementine partnered with singer and songwriter Becky Hill to encourage young people on a journey to self-care.

Headquartered in London, Clementine raised $1.3m (£1m) in its seed funding round in October 2020.

Because women are not just consumers but the primary healthcare decision-makers for themselves and often for their families, better health outcomes for women can lead to better outcomes for society.

In sickness and in health, at RAPP we stand up for individuality to co-create better outcomes for all. We leverage deep understanding of the realities, values and intersectional identities creates personalised and connected brand experiences that drive healthier outcomes. We believe that predictive, preventive and inclusive health is enabled by creativity, behavioural science, data and technology.

 

Menopause

Many women still confused about perimenopause, research finds

Published

on

One in three US women older than 35 are no sure whether they are in perimenopause, new research has revealed.

The findings suggest uncertainty remains common, largely because of knowledge gaps, symptom confusion and difficulty getting confirmation or care.

Perimenopause is the transitional stage before a woman’s final period, when hormone levels fluctuate and symptoms can change over time.

It usually begins in the mid-40s, although timing varies widely, and can last for around four to eight years.

Symptoms can include hot flushes, psychological symptoms and urogenital symptoms, which affect the urinary and genital areas.

Dr Stephanie Faubion, medical director for The Menopause Society and one of the study authors, said: “This large study showed that one in three US women aged older than 35 years are not sure whether they are in perimenopause.

“Further, the study highlights that symptom confusion, misconceptions, and barriers to care are leaving many women without the clarity and support they need during the menopause transition.

“Recognising perimenopause uncertainty as a common experience can help shift the conversation from searching for a diagnosis to providing women with the information, validation, and support they need to navigate this natural life transition with confidence.”

More than 7,600 US women aged 35 and older took part in the study, which looked at how common uncertainty around perimenopause is and what may be driving it.

Overall, 34 per cent of participants said they were unsure of their reproductive stage.

Uncertainty varied by age and symptom burden, reaching 42 per cent among women aged 40 to 44 and 37 per cent among those with severe symptoms.

Symptom confusion was the most common factor, cited in 56 per cent of responses.

This included difficulty making sense of bodily changes and telling perimenopause apart from other possible causes, such as premenstrual syndrome, thyroid disease or mental health conditions.

Knowledge gaps and information-seeking made up 28 per cent of responses, reflecting limited awareness, age-based assumptions and attempts to find reliable information.

Barriers to confirmation and care made up 16 per cent, including dismissive healthcare encounters and reluctance to acknowledge perimenopause.

Younger women aged 35 to 39 were more likely to cite knowledge gaps, while healthcare barriers were most common among women aged 40 to 44.

The researchers said clinicians should take a more flexible approach to recognising the emotional, cognitive and physical symptoms that can occur during perimenopause.

They said healthcare professionals should not rely too heavily on irregular periods as the main sign, because some women have symptoms before major cycle changes.

 

Continue Reading

News

New menopause drug approved for use by NHS in Scotland

Published

on

A new menopause drug has been approved for NHS use in Scotland, offering a non-hormonal option for women who cannot take HRT.

The Scottish Medicines Consortium has recommended that women can now be prescribed fezolinetant, also known as Veoza, for symptoms such as hot flushes and night sweats.

Some women cannot take HRT, leaving them with limited treatment options for symptoms that can be severe and long-lasting.

Dr Timir Patel, medical director of Astellas UK, said the company was “pleased that this important additional treatment option will be available to women in Scotland, helping to support more personalised care for those experiencing hot flushes and night sweats”.

Fezolinetant works by selectively blocking a neurotransmitter in the brain involved in triggering hot flushes.

Clinical trials have shown the drug can reduce both the frequency and severity of hot flushes and night sweats.

About 400,000 women in Scotland are said to be of menopausal age, with manufacturer Astellas Pharma Ltd saying up to 48,000 could benefit from the treatment.

Dr Rob Peel, chair of the Scottish Medicines Consortium, said: “We know that menopausal hot flushes and night sweats can substantially affect quality of life.

“For those who cannot take HRT, effective treatment options are limited. Fezolinetant provides a non-hormonal treatment option, and we know our decision will be welcomed.”

Dr Kay McAllister, consultant gynaecologist and clinical lead for menopause services at NHS Glasgow and Greater Clyde, said: “Today’s decision marks a positive development for the wellbeing of Scottish women.

“In clinical practice, I see how hot flushes and night sweats impact sleep and overall quality of life in my patients.

“The availability of this targeted treatment offers a welcome choice and further options for patients.”

Continue Reading

News

Avni Wellness secures US$470k funding

Published

on

Avni Wellness has secured Rs 4 crore, around US$470,000, in seed funding to expand its products and digital commerce capabilities.

The Mumbai-based women’s health start-up plans to strengthen its online retail operations and increase its presence across digital marketplaces.

It will also expand its cycle nutrition product range and grow its women-led network of micro-entrepreneurs.

Founded in 2021 by Sujata Pawar and Apurv Agarwal, Avni Wellness offers science-backed, toxin-free products spanning adolescence, reproductive years and menopause.

Its portfolio includes a patented antimicrobial reusable sanitary pad and a liposomal iron supplement designed to address iron deficiency among women in India.

Liposomal supplements encase nutrients in tiny fat-like particles intended to support absorption.

The company also offers products for polycystic ovary syndrome, or PCOS, calcium supplementation, urinary and vaginal health and seed-based hormonal nutrition. PCOS is a condition that can affect hormone levels, periods and fertility.

Proteus Partners led the funding round, with participation from angel investors Puru Gupta, Sreejith Moolayil, A. Velumani and Somya Nigam.

Avni Wellness said it aims to address gaps in women’s healthcare in India by focusing on hormonal health, nutrition and long-term wellbeing while incorporating livelihood generation and sustainability into its model.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.